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Streptococcus (S.) agalactiae colonizes in the female genitourinary and lower gastrointestinal tracts and is
responsible for a wide range of infections in newborns, pregnant women and non-pregnant adults.
Therefore, antibiotic prophylaxis and infection treatment against S. agalactiae is important. The aim of
this study was to determine the prevalence of S. agalactiae antibiotic resistance in Iranian patients,
especially among pregnant women. A systematic literature search was conducted in PubMed, Scopus,
Google Scholar and the Scientific Information Database (SID) databases by using related keywords and
without any time limitation. A total of 26 studies reporting the prevalence of S. agalactiae antibiotic
resistance in Iran met our predefined inclusion and exclusion criteria and were included in the meta-
analysis. High rates of S. agalactiae antibiotic resistance in pregnant women were found against tetra-
cycline (96.2%), trimethoprim-sulfamethoxazole (84.7%), cefotaxime (41.3%), clindamycin (26.8%) and
erythromycin (21%). Additionally, resistance to penicillin (4.2%), ampicillin (2.7%), cefazolin (7.6%), van-
comycin (2.4%), ceftriaxone (12.5%), ciprofloxacin (13.6%) and nitrofurantoin (0%) was low. Our results
revealed that penicillin and ampicillin among penicillin-tolerant Iranian pregnant women, and vanco-
mycin and cefazolin among penicillin-allergic women are still drugs of choice in intrapartum prophylaxis
for preventing S. agalactiae vertical transmission and early-onset neonatal disease.
© 2020 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Streptococcus (S.) agalactiae is a Gram-positive, b-hemolytic,
facultative anaerobe and catalase-negative bacterium that has the
group B antigen in the cell wall [1,2]. The natural habitat of this
group B streptococcus (GBS) is in the urogenital tract and lower
gastrointestinal tract. This microorganism can also be colonized in
the vagina in 10e30% of pregnant women [1e3]. S. agalactiae is
associated with life-threatening infections in both newborn chil-
dren and adults including pregnant and non-pregnant women and
men [3]. Early-onset neonatal disease occurs during the first 7 days
of life and is characterized by bacteremia, pneumonia and menin-
gitis. The disease is acquired in the uterus or during vaginal deliveryy, School of Medicine, Ardabil
5618985991, Ardabil, Iran.
@yahoo.com (F. Khademi).
Gynecology. Publishing services bfrom asymptomatic mothers. Late-onset neonatal disease occurs
between the first week and the third month of life and is charac-
terized by bacteremia with meningitis [1,2]. Adult diseases include
endometritis, wound infections and urinary tract infections in
pregnant women, as well as bacteremia, pneumonia, bone and joint
infections, and skin and soft tissue infections in men and non-
pregnant women [2]. The mortality rate is low among infants due
to rapid diagnosis and varies between 2% and 4%; however, severe
neurological sequelae may occur in 15e30% of infants [2,4]. Previ-
ous studies have estimated the maternal S. agalactiae colonization
rate to be 18.0% globally [5]. This colonization ratewas 15.5% among
Iranian pregnant women [3]. According to the Centers for Disease
Control and Prevention (CDC) guideline, vaginal-rectal screening
should be performed in all pregnant women at weeks 35e37 of
pregnancy for the prevention of perinatal GBS infection [6]. Intra-
partum antibiotic prophylaxis is recommended in high-risk preg-
nant women in order to prevent maternal colonization of GBS [5].
For high-risk pregnant womenwith 1) history of childbearing with
GBS infections, 2) GBS bacteriuria and positive culture for GBS iny Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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preterm birth or rupture of membranes before childbearing (before
37 weeks) and 5) prolonged rupture of membranes more than 18 h
after 37 weeks, chemoprophylaxis with intravenous penicillin G or
ampicillin is recommended to prevent early-onset neonatal disease
[2,6,7]. Additionally, to prevent penicillin-associated allergic re-
actions, cefazolin, clindamycin and vancomycin can be used in
penicillin-allergic women [2]. b-lactam antibiotics, especially
penicillin and ampicillin, are two drugs of choice for treating GBS
infections [2]. Despite a 70% reduction in perinatal GBS infection
incidence, there are serious concerns for emerging antibiotic
resistance among GBS bacteria due to intrapartum antibiotic pro-
phylaxis [8,9]. It should be noted that treating GBS infection with
tetracyclines, macrolides and clindamycin is not recommended due
to increased level of antibiotic resistance [2]. There has been no
comprehensive data on S. agalactiae antibiotic resistance in Iran.
Therefore, the objective of the present systematic review andmeta-
analysis was to increase our awareness regarding the epidemiology
of S. agalactiae antibiotic resistance, especially in pregnant women,
in Iran.Materials and methods
Search strategy and study selection
We conducted the current meta-analysis based on the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
guideline [10]. A list of the studies was collected in a reference
management software by two authors independently through
searching in different databases including PubMed, Scopus, Google
Scholar and the Scientific Information Database (SID). There was no
date limitation for searching electronic resources. Search terms
were “antibiotic resistance’’ OR “drug resistance’’ AND
“S. agalactiae’’ OR “S. agalactiae’’ OR “group B streptococcus (GBS)”
AND “newborns” AND “pregnant women” AND “non-pregnant
women” AND “men” AND “Iran”. The search was managed through
establishing an archive of relevant studies on S. agalactiae drug
resistance in Iran by screening the titles and abstracts of the articles
retrieved based on inclusion and exclusion criteria. Published
cross-sectional studies in a language other than Persian and English
languages, reporting antibiotic resistance of S. agalactiae isolated
from samples other than clinical specimens and reporting anti-
biotic resistance of S. agalactiae from other countries were excluded
from themeta-analysis. Articles with incomplete data, case reports,
review articles and duplicate reports were also excluded. The
reference lists of included articles were further checked to find any
additional relevant study. The project was evaluated by Ardabil
University of Medical Sciences and found to be in accordance to the
ethical principles and the national norms and standards for con-
ducting Medical Research in Iran (IR.ARUMS.REC.1398.127; 2019-
06-23).Data extraction and quality assessment
Relevant information obtained from the eligible studies
included location of the study, year of the study, sample type, pa-
tients’ properties, number of isolated S. agalactiae strains, antimi-
crobial susceptibility testing technique and drug resistance rates of
S. agalactiae strains. The Joanna Briggs Institute (JBI) critical
appraisal checklist was used to evaluate the quality of included
cross-sectional studies. The quality of studies was classified as high
(scores >5), medium (scores between 4 and 5) or low (scores <4).Statistical analysis
Comprehensive Meta-Analysis software (Biostat, Englewood,
NJ) was used for pooling of data and calculating antibiotic resis-
tance rates, heterogeneity and publication bias in the meta-
analysis. Percentage of S. agalactiae resistance to different antibi-
otics was calculated and expressed as 95% confidence interval (CI).
Inconsistency among included studies was expressed as percentage
(%) using I2 statistic. If I2 score was >25%, pooling of data was done
by using random-effectsmodel. Publication bias was assessed using
funnel plots.
Results
Study selection
A total of 1091 articles, 1061 articles from international data-
bases and 30 articles from an Iranian database, were identified
(Fig. 1). Of these, 882 duplicate articles were removed by Endnote
and 209 articles were evaluated based on the titles and abstracts.
After screening the titles and abstracts, 157 articles did not meet
our inclusion criteria and were excluded due to the fact that they
were not relevant articles and reported the prevalence of
S. agalactiae infection, S. agalactiae drug resistance in non-clinical
samples and were not original articles. Thus, 52 full-text of the
articles were assessed for eligibility. Of these, 28 articles were
excluded with reasons such as inadequate data, not online avail-
ability of full-text of the article and abstract list of congresses. An
additional 2 articles were added from searching reference lists of
the included articles. Finally, there were 26 articles totally included
in this meta-analysis with quality scores between 4 and 8.
Study characteristics
The 26 studies from 12 cities of Iran including Arak (n ¼ 3),
Ardabil (n ¼ 2), Hamadan (n ¼ 3), Kashan (n ¼ 1), Kermanshah
(n ¼ 1), Kerman (n ¼ 1), Khorramabad (n ¼ 1), Mashhad (n ¼ 1),
Salmas (n ¼ 1), Tehran-Alborz (n ¼ 11) and Yazd (n ¼ 1) were
included in this study. Based on the data presented in Table 1,
S. agalactiae strains were collected fromdifferent clinical specimens
including vaginal and rectal swabs, urine, skin and soft tissue, bone,
joint, blood, cerebrospinal fluid (CSF), pleural fluid, throat and
external ear canals. Samples were also collected from newborns,
pregnant women and non-pregnant adults. Additionally, microbi-
ological methods including growth on Todd-Hewitt-Broth or 5%
sheep blood agar mediums with 5% CO2 at 33e37 C for 18e24 h,
typical colony morphology, Gram staining, b-hemolysis and other
standard biochemical methods including negative catalase, positive
hippurate hydrolysis and the Christie-Atkins-Munch-Petersen
(CAMP) tests, bile esculin and 6.5% NaCl tests and finally resis-
tance to trimethoprim-sulfamethoxazole and bacitracin disks were
used for identifying S. agalactiae strains.
As shown in Fig. 3, funnel plot of the meta-analysis on the
prevalence of antibiotic resistance of S. agalactiae to penicillin (A)
and ampicillin (B) showed some evidence for publication bias due
to asymmetric shape of funnel plots.
Characteristics of S. agalactiae antibiotic resistance
As presented in Table 1, KirbyeBauer's disk diffusion method
along with E-test and agar dilution methods were used to deter-
mine S. agalactiae antibiotic resistance characteristics in Iran. Based
on the current meta-analysis, S. agalactiae resistance to different
antibiotics among Iranian patients were as follows: 3.9% (95% CI:
1.1e13.0; I2 ¼ 95.1%; P ¼ 0.0) to penicillin (Fig. 2A), 7.1% (95% CI:
Fig. 1. The four-phase flow diagram of study selection process.
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19.0e34.5; I2 ¼ 89.8%; P ¼ 0.0) to erythromycin, 30.7% (95% CI:
20.0e43.9; I2 ¼ 94.3%; P ¼ 0.0) to clindamycin, 3.2% (95% CI:
1.6e6.5; I2 ¼ 77%; P ¼ 0.0) to vancomycin, 7.5% (95% CI: 2.7e19.3;
I2 ¼ 80%; P ¼ 0.0) to cefazolin, 25.1% (95% CI: 12.7e43.5; I2 ¼ 85.7%;
P ¼ 0.0) to ceftriaxone, 18.5% (95% CI: 4.4e52.5; I2 ¼ 93.3%; P ¼ 0.0)
to ciprofloxacin, 70.6% (95% CI: 60.1e79.3; I2 ¼ 53.7%; P ¼ 0.0) to
trimethoprim-sulfamethoxazole, 46.1% (95% CI: 41.9e50.3;
I2 ¼ 0.0%; P ¼ 0.0) to cefotaxime, 90.7% (95% CI: 85.4e50.3;
I2¼ 94.2%; P¼ 0.0) to tetracycline, 3.5% (95% CI: 1.5e7.9; I2¼ 36.2%;
P ¼ 0.16) to nitrofurantoin, 31.5% (95% CI: 18.7e47.9; I2 ¼ 84.9%;
P ¼ 0.0) to chloramphenicol, 0% to quinupristin/dalfopristin, 4.9%
(95% CI: 3.2e7.5; I2 ¼ 0.0%; P ¼ 0.63) to levofloxacin and 0.08% (95%
CI: 0.02e0.20; I2 ¼ 0.0%; P ¼ 0.63) to linezolid. Additionally, other
antibiotic resistance patterns were as follows: azithromycin 41.9%
(95% CI: 30.4e54.5), doxycycline 99.2% (95% CI: 88.5e100.0), cef-
tazidime 5.0% (95% CI: 1.6e14.4), ceftizoxime 54.1% (95% CI:
38.1e69.3), cephalothin 8.6% (95% CI: 0.8e51.2), norfloxacin 12.7%
(95% CI: 0.8e73.5), moxifloxacin 8.9% (95% CI: 4.5e16.8), cefixime
80.2% (95% CI: 50.9e94.0), gentamicin 85.6% (95% CI: 60.6e95.8),
kanamycin 66.6% (95% CI: 6.5e98.3), amikacin 81.1% (95% CI:
20.6e98.6), nalidixic acid 99.3% (95% CI: 89.2e100.0) and cepha-
lexin 29.2% (95% CI: 0.6e96.7). Additionally, the prevalence rates of
GBS drug resistance in pregnant womenwere as follows: 4.2% (95%
CI: 1e16.2; I2 ¼ 68.7%; P ¼ 0.0) to penicillin, 2.7% (95% CI: 0.5e13.6;
I2 ¼ 78.7%; P ¼ 0.0) to ampicillin, 21% (95% CI: 9.2e41.1; I2 ¼ 82.8%;
P ¼ 0.0) to erythromycin, 26.8% (95% CI: 12.9e47.6; I2 ¼ 82.6%;
P¼ 0.0) to clindamycin, 2.4% (95% CI: 0.9e6.4; I2¼ 0.0%; P¼ 0.47) to
vancomycin, 7.6% (95% CI: 1.6e30; I2 ¼ 83.4%; P ¼ 0.0) to cefazolin,
12.5% (95% CI: 6.1e24; I2 ¼ 0.0%; P ¼ 1.0) to ceftriaxone, 13.6% (95%
CI: 7.1e24.5; I2 ¼ 0.0%; P ¼ 0.54) to ciprofloxacin, 84.7% (95% CI:
73.5e91.7; I2 ¼ 0.0%; P ¼ 0.48) to trimethoprim-sulfamethoxazole,
41.3% (95% CI: 27.7e56.5; I2 ¼ 21%; P ¼ 0.26) to cefotaxime, 96.2%
(95% CI: 87.8e98.9; I2 ¼ 0.0%; P ¼ 0.68) to tetracycline and 0% to
nitrofurantoin.Discussion
S. agalactiae is associated with a wide range of infections in
newborns, pregnant women and non-pregnant adults. Therefore,
antibiotic prophylaxis in pregnancy and during vaginal birth, and
post-delivery infections treatment against S. agalactiae are impor-
tant. According to the guidelines from CDC, S. agalactiae remains
susceptible to penicillin, ampicillin and first-generation cephalo-
sporins [7]. Penicillin and ampicillin are two highly effective anti-
biotics in S. agalactiae intrapartum prophylaxis, which are
intravenously administered for 4 h before delivery to prevent
S. agalactiae vertical transmission and early-onset neonatal disease
[7]. In this study, 3.9% and 7.1% of S. agalactiae strains isolated from
the Iranian patients were resistant to penicillin and ampicillin
(Fig. 2A and B). Resistance rate to these b-lactam antibiotics in this
study was lower than that reported from Italy [37], while being
higher compared to those reported from China [38], Switzerland
[39], Brazil [40] and the Netherlands [41]. On the other hand,
resistance to penicillin (4.2%) was higher and to ampicillin (2.7%)
was notably lower among pregnant women compared to overall
resistance rates (3.9% and 7.1%) in Iran. Therefore, these antibiotics
can still be administered for intrapartum prophylaxis against
S. agalactiae in the Iranian pregnant women with no risk for
anaphylaxis. In penicillin-allergic mothers, macrolides (erythro-
mycin), lincosamides (clindamycin), glycopeptides (vancomycin)
and first-generation cephalosporins (cefazolin) are recommended
for prophylaxis but their efficacy is unknown [7]. In the current
meta-analysis, overall GBS resistance to erythromycin and clinda-
mycin among Iranian patients were 26% and 30.7%, respectively.
Furthermore, in the Iranian pregnant women, resistance to eryth-
romycin (21%) and clindamycin (26.8%) was high. Resistance rate to
these antibiotics was lower than Italy [37] and China [38] but
higher than Switzerland [39], Brazil [40], the Netherlands [41] and
Chile [42]. Total prevalence of vancomycin- and cefazolin-resistant
S. agalactiae was low, being 3.2% to vancomycin and 7.5% to
Fig. 2. Forest plot of the meta-analysis on the prevalence of antibiotic resistance of S. agalactiae to penicillin (A) and ampicillin (B) in Iran.
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Fig. 3. Funnel plot of the meta-analysis on the prevalence of antibiotic resistance of S. agalactiae to penicillin (A) and ampicillin (B) in Iran.
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Table 1
Profiles of included studies in the meta-analysis.
Area Year Sample type Patients' properties Strain (n) AST Antibiotic resistance (n) Ref
PEN AMP ERY CLI VAN CFZ CRO CIP TMP/SXT CTX TET NIT CHL Q-D LVX LZD
Arak 2013 Vaginal and rectal swabs Pregnant women 60 Disk diffusion 0 0 17 9 0 2 ND ND ND ND 58 ND ND ND ND ND [11]
Arak 2010 Vaginal and rectal swabs Pregnant women 30 Disk diffusion 0 11 7 ND 0 12 NA ND ND 14 ND ND ND ND ND ND [12]
Arak ND Vaginal and rectal swabs Pregnant women 14 Disk diffusion 14 0 8 13 0 3 ND ND ND 4 ND ND ND ND ND ND [13]
Ardabil 2008 Vaginal and rectal swabs Pregnant women 56 Disk diffusion
E-test
0 0 0 2 0 0 7 8 47 ND ND ND ND ND ND ND [14]
Ardabil 2008 Vaginal and rectal swabs Pregnant women 62 Disk diffusion
E-test
0 0 1 11 0 ND ND ND ND ND ND ND ND ND ND ND [15]
Hamadan 2013e2014 Vaginal swab
Urine
Blood
Pregnant and
none-pregnant women
62 Disk diffusion 0 0 22 0 0 0 ND ND ND ND 62 ND 2 0 3 0 [16]
Hamadan 2013e2014 Urine ND 2 Disk diffusion ND ND ND ND 0 0 0 1 0 0 ND 0 ND ND ND ND [17]
Hamadan 1998e2002 ND ND 13 Disk diffusion ND 3 ND ND ND ND ND ND 6 ND ND ND 9 ND ND ND [18]
Kashan 2011e2012 Vaginal swab Pregnant women 36 Disk diffusion 0 0 2 3 ND 0 ND ND ND ND ND ND ND ND ND ND [19]
Kermanshah ND Vaginal swab Pregnant women 6 Disk diffusion 1 ND 3 2 1 ND ND ND ND ND ND ND ND ND ND ND [20]
Kerman 2006e2007 Vaginal swab Pregnant women 55 Agar dilution 0 0 6 14 ND ND ND ND ND ND ND ND ND ND ND ND [21]
Khorramabad 2012 Vaginal and rectal swabs Pregnant women 22 Disk diffusion 1 ND 22 22 0 ND ND ND ND ND ND ND ND ND ND ND [22]
Mashhad ND Vagina, urethra and
prostate secretion
Urine
ND 66 Disk diffusion
E-test
18 0 16 13 2 ND 0 ND ND ND ND ND ND ND ND ND [23]
Salmas 2015 Urine None-pregnant women
and Men
47 Disk diffusion ND 29 ND 41 ND ND ND 25 35 ND 36 3 ND ND ND ND [24]
Tehran-Alborz 2014e2015 Vaginal swab
Urine
Blood
Spermatic fluid
Pregnant and
none-pregnant women
90 Disk diffusion 0 ND 27 89 1 ND ND ND ND ND 89 ND ND ND 6 ND [25]
Tehran 2013e2015 Urine
Skin and soft tissue Bone
Joint
Blood
CSF
Pleural fluid
ND 222 Disk diffusion 0 0 127 149 0 ND ND ND ND ND 194 ND 73 ND ND ND [26]
Tehran 2014 Urine ND 264 Disk diffusion 0 1 43 38 0 ND ND 13 ND ND 212 1 ND ND 11 0 [27]
Tehran 2013 Throat External ear canals Newborns 19 Disk diffusion 0 ND 5 6 0 ND ND ND ND ND 19 ND ND 0 ND 0 [28]
Tehran 2012e2013 Urine ND 28 Disk diffusion ND 10 27 ND 0 ND 15 ND 19 ND ND 0 7 ND ND ND [29]
Tehran 2011e2012 Urine ND 104 Disk diffusion ND ND 22 24 ND ND ND ND ND ND ND ND ND ND ND ND [30]
Tehran 2010e2011 Vaginal and rectal swabs Pregnant women 7 Disk diffusion 0 0 ND ND ND ND ND 0 7 ND 7 0 ND ND ND ND [31]
Tehran 2010 Urine ND 115 Disk diffusion 0 ND 40 40 ND ND ND ND ND ND 110 ND 51 0 ND 1 [32]
Tehran 2010 Urine Pregnant and
none-pregnant women
498 Disk diffusion 445 251 120 84 80 ND 218 ND ND 232 ND ND ND ND ND ND [33]
Tehran 2010 Urine ND Variable ND ND 7 ND ND 9 16 ND ND 126 ND 146 7 ND ND ND ND [34]
Tehran ND Vaginal swab
Urine
ND 50 Disk diffusion 18 21 8 9 12 ND 12 ND ND ND ND ND ND ND ND ND [35]
Yazd 2015 Vaginal swab Pregnant and
none-pregnant women
100 Disk diffusion 1 ND 8 10 ND ND ND ND ND ND 95 ND ND ND ND ND [36]
Abbreviations: PEN-penicillin; AMP-ampicillin; ERY-erythromycin; CLI-clindamycin; VAN-vancomycin; CFZ-cefazolin; CRO-ceftriaxone; CIP-ciprofloxacin; TMP/SXT-trimethoprim-sulfamethoxazole; CTX-cefotaxime; TET-
tetracycline; NIT-nitrofurantoin; CHL-chloramphenicol; Q-D-quinupristin/dalfopristin; LVX-levofloxacin; LZD-linezolid; ND-not determined; AST-antimicrobial susceptibility testing; CSF-cerebrospinal fluid.
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cefazolin-resistant S. agalactiae among Iranian pregnant women
were 2.4% and 7.6%, respectively. According to the results of this
study, due to high rates of erythromycin and clindamycin resis-
tance, vancomycin and cefazolin are drugs of choice in intrapartum
prophylaxis among penicillin-intolerant Iranian pregnant women.
S. agalactiae resistance to other cephalosporins such as cepha-
lexin (29.2%), ceftriaxone (25.1%), cefotaxime (46.1%), ceftizoxime
(54.1%) and cefixime (80.2%) was high, except for cephalothin
(8.6%) and ceftazidime (5.0%). One possible reason for the high rate
of resistance of this bacterium is lower effectiveness of cephalo-
sporins on Gram-positive bacteria [1,2]. In our study, cephalothin,
cefotaxime and ceftriaxone resistance rates were higher than those
reported from China (0%), Brazil (0%) and the Netherlands (0%)
[38,40,41].
We observed a lower percentage of resistance to quinupristin/
dalfopristin and linezolid, while resistance to other protein syn-
thesis inhibitors including azithromycin, doxycycline, tetracycline,
chloramphenicol, gentamicin, kanamycin and amikacinwas higher.
The same rate of linezolid resistance (0.08%) was found in Italy (0%)
and Switzerland (0%) [37,43]. Also, tetracycline resistance rate
(90.7%) was similar to those of China (83.9%), Brazil (97.0%) and
Switzerland (89.0%) [38,40,43]. However, azithromycin resistance
rate (41.9%) was lower than that of China (87.5%) [38], and genta-
micin resistance rate (85.6%) was higher than that of Switzerland
(0.8%) [43].
The prevalence of S. agalactiae resistance to quinolones was
variable. Resistance rate to the narrow-spectrum quinolone, nali-
dixic acid, was found to be high (99.3%) in the current study. This is
an expected result because nalidixic acid is an effective quinolone
against Gram-negative rods and has no activity against Gram-
positive bacteria [2]. Our results also showed that S. agalactiae
resistance to broad-spectrum quinolones including levofloxacin
(4.9%) and ciprofloxacin (18.5%) as well as extended-spectrum
quinolones including norfloxacin (12.7%) and moxifloxacin (8.9%)
was low. These results are also in accordance with the fact that
antimicrobial activity of broad- and extended-spectrum quinolones
is higher against Gram-positive bacteria [2]. S. agalactiae resistance
rates to quinolones in other countries were reported to be as fol-
lows: Italy: levofloxacin 9.23% and moxifloxacin 0% [37], China:
levofloxacin 35.7% [38], Brazil: levofloxacin 0% [40], and
Switzerland: levofloxacin 1.6% [43]. In the present study, nitro-
furantoin resistance rate was 0%, which is similar to that reported
by Simoes et al. [44]. Therefore, nitrofurantoin can be a drug of
choice for treating asymptomatic and symptomatic bacteriuria in
the Iranian pregnant women due to low resistance rate and its
ability to achieve adequate concentrations in the urine [44]. How-
ever, it is not useful in intrapartum prophylaxis due to its low level
in the maternal bloodstream and inability to cross the placenta
[44]. However, 84.7% of S. agalactiae were resistant to
trimethoprim-sulfamethoxazole, suggesting that it is not an effec-
tive drug for treating urinary tract infection in the Iranian pregnant
women. We observed variable resistance rates to this drug in
different studies. This difference may be due to differences in the
geographical area, patients’ properties and specimen type. Lack of
access to complete data from all cities of Iran on S. agalactiae
antibiotic resistance and a high level of heterogeneity among the
included studies were the main limitation of the current systematic
review and meta-analysis.
Conclusion
Given the low prevalence of S. agalactiae resistance to penicillin
and ampicillin in the Iranian pregnant women, these antibiotics can
still act as two highly effective antibiotics in intrapartumprophylaxis for preventing S. agalactiae vertical transmission and
early-onset neonatal disease in Iran. Furthermore, due to the high
rate of erythromycin and clindamycin resistance, vancomycin and
cefazolin are drugs of choice for intrapartum prophylaxis in
penicillin-allergic Iranian women. Additionally, resistance rates to
nitrofurantoin, quinupristin/dalfopristin, levofloxacin, linezolid,
ceftazidime, norfloxacin, cephalothin andmoxifloxacinwere low in
Iran; therefore, using these agents is suggested for the treatment of
S. agalactiae infections. Investigation of bacterial resistance mech-
anisms especially among resistant bacteria to erythromycin, clin-
damycin, ceftriaxone, ciprofloxacin, trimethoprim-
sulfamethoxazole, cefotaxime, tetracycline, chloramphenicol, azi-
thromycin, doxycycline, ceftizoxime, cefixime, gentamicin, kana-
mycin, amikacin, nalidixic acid and cephalexin is recommended.Declaration of Competing Interest
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